WindRose Health Investors Recapitalizes Verified Clinical Trials, Appoints Howard Miller as CEO to Accelerate Growth
核心洞察
WindRose Health Investors (搜索) has completed the recapitalization of Verified Clinical Trials (搜索) (VCT), a global leader in clinical trial subject registry solutions.
Howard Miller, former CEO of Envision Pharma Group (搜索), has been appointed as VCT's new Chief Executive Officer to lead the next phase of growth.
Co-founders Mitchell Efros, MD, and Kerri Weingard, ANP, will remain actively involved, transitioning to roles focused on long-term strategy and client relationships.
WindRose Health Investors (搜索), the New York-based healthcare private equity firm with approximately $8 billion under management, announced on August 6, 2026, that it has completed the recapitalization of Verified Clinical Trials (搜索), LLC (VCT), the global leader in solutions addressing patient safety, compliance, and data integrity from patient enrollment through study completion. The terms of the transaction were not disclosed.
As part of the transaction, WindRose will appoint Howard Miller as Chief Executive Officer. Miller brings more than 30 years of experience leading healthcare and life sciences companies, including serving as CEO of Envision Pharma Group (搜索), COO and then CEO at Two Labs, and holding sales and marketing leadership roles at Abbott (搜索), Cardinal Health, and Novavax.
Co-founders Mitchell Efros, MD, and Kerri Weingard, ANP, will remain actively involved in the business. Mitchell will serve as President and Co-Founder, focusing on client relationships and enhancement of the company's value proposition, while Kerri will serve as Chief of Strategic Operations, concentrating on driving continuous improvement at scale.
A Platform Built on Patient Safety and Data Integrity
VCT's industry-recognized subject registry platform is designed to detect and help prevent duplicate enrollment and other protocol violations at the time of screening — issues that compromise research subject safety, affect data quality, create operational and regulatory challenges, and increase the risk of study failure. The company's secure global database is trusted by research sites, sponsors, and contract research organizations (CROs) to help improve research subject safety, strengthen protocol compliance, and protect data integrity.
"This partnership with WindRose marks an exciting new chapter for VCT. Over the past 16 years, VCT has developed proprietary data assets and processes that have become essential to protecting patient safety and data integrity in clinical research," said Mitchell Efros, MD and Kerri Weingard, ANP, Co-Founders of VCT.
Strategic Growth and Expanded Capabilities
With WindRose's investment, VCT is positioned to capitalize on the rapidly growing adoption of its solutions, as well as further develop additional data and analytics capabilities to better serve pharmaceutical sponsors, CROs, and clinical trial sites. The company will maintain its name, brand, and commitments to safety, data quality, and strong client partnerships, but will have additional capital to support investment in infrastructure and expansion of services and geographic reach.
"VCT has developed a truly unique solution that proactively reduces downstream risk for all clinical research constituents — driving safety for participants, improved data quality, and reduction in preventable trial disruptions," said CJ Burnes, Partner at WindRose. "We are excited to partner with Howard, Mitchell and Kerri and accelerate VCT's growth with further investment in the Company's platform and capabilities."
Howard Miller expressed his conviction about the company's trajectory: "VCT brings significant value to all stakeholders through its proprietary subject registry technology, and I have strong conviction that broader utilization of the Company's services will accelerate the delivery of safe, innovative treatments to patients who need them."
The co-founders emphasized their long-term vision, stating: "WindRose's deep healthcare expertise and Howard's strong track record of scaling high growth businesses and developing high-performing teams makes them an ideal partner. We look forward to making our subject verification solution the gold standard in clinical trial compliance so that we can help sponsors, CROs and sites bring safe, effective therapies to patients faster."
Cantor Fitzgerald & Co. (搜索) acted as exclusive financial advisor to VCT. McDermott Will & Schulte LLP served as legal advisor to VCT, while Latham & Watkins LLP served as legal advisor to WindRose.